CASI Pharmaceuticals, Inc.
CASIF · PNK
Market closed$0.170000$0.020000 (+13.33%)After hours $0.170000 · 0.00%
Key statistics
Previous close$0.150000
Open$0.166000
Day high$0.170000
Day low$0.134400
52-week high$3.09
52-week low$0.050000
Market cap3.49M
Volume1.00
Average volume9.41K
P/E ratio-0.06
Forward P/E—
EPS-2.68
Dividend yield0.00%
Market context
Why it moved
CASIF's sharp price surge today appears to be driven by renewed speculative buying interest and low-float trading dynamics, as no specific fundamental catalyst was identified, but momentum traders pushed the stock significantly higher on elevated relative volume.
What is happening
Recent company-specific developments and publisher coverage.
Investing News Network · February 25, 2026CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings PanelStock Titan · February 25, 2026CASI loses Nasdaq listing, pursues OTC trading after panel rulingInvesting News Network · January 12, 2026CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune ThrombocytopeniaNewswire.com · July 21, 2025CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 ProgramPR Newswire · June 26, 2024CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu HeClinical Trials Arena · February 19, 2024CASI begins dosing lymphoma patients with pralatrexate in China Benzinga · February 26, 2026What Drove CASI Pharmaceuticals' 24% Rise After Hours? Benzinga · February 25, 2026CASI Pharmaceuticals To Be Delisted From Nasdaq, Effective Feb. 26 Benzinga · January 22, 2026CASI Pharmaceuticals Fails To Renew FOLOTYN Import License In China, Halting Sales Benzinga · January 15, 2026CASI Pharmaceuticals Gets China National Medical Products Administration's Approval To Start Phase1/2 Clinical Study For CID-103 In Adults With Chronic Active Renal Allograft Antibody-Mediated Rejection Benzinga · December 8, 2025CASI Pharmaceuticals Highlights Results From CID-103 Immune Thrombocytopenia Study Study At Annual ASH Meeting Benzinga · September 3, 2025HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target Benzinga · August 29, 202512 Health Care Stocks Moving In Friday's After-Market Session Benzinga · August 29, 2025CASI Pharmaceuticals Q2 EPS $(0.86) Misses $(0.47) Estimate, Sales $4.175M Miss $6.300M Estimate